iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Balaxi Pharmaceuticals consolidated net profit rises 28.55% in the September 2022 quarter

5 Nov 2022 , 04:09 PM

Net profit of Balaxi Pharmaceuticals rose 28.55% to Rs 15.49 crore in the quarter ended September 2022 as against Rs 12.05 crore during the previous quarter ended September 2021. Sales rose 23.00% to Rs 86.38 crore in the quarter ended September 2022 as against Rs 70.23 crore during the previous quarter ended September 2021.

Particulars Quarter Ended
? Sep. 2022 Sep. 2021 % Var.
Sales 86.38 70.23 23
OPM % 17.08 19.98
PBDT 18.87 14.15 33
PBT 18.68 14.03 33
NP 15.49 12.05 29

Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.